These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20130429)

  • 21. Endocrine therapy--current benefits and limitations.
    Nicholson RI; Johnston SR
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
    Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary experience with pure antiestrogens.
    Howell A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of hormone sensitivity for breast cancers.
    Miyoshi Y; Murase K; Saito M; Oh K
    Breast Cancer; 2010 Apr; 17(2):86-91. PubMed ID: 19806427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
    Cleator SJ; Ahamed E; Coombes RC; Palmieri C
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
    Roop RP; Ma CX
    Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
    Hurvitz SA; Pietras RJ
    Cancer; 2008 Nov; 113(9):2385-97. PubMed ID: 18819158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant endocrine therapy for the surgeon: options, side effects, and their management.
    Connor C; Attai D
    Ann Surg Oncol; 2013 Oct; 20(10):3188-93. PubMed ID: 23975307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
    Ziauddin MF; Hua D; Tang SC
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
    Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of renin angiotensin system on tamoxifen resistance.
    Namazi S; Ardeshir-Rouhani-Fard S; Abedtash H
    Med Hypotheses; 2011 Jul; 77(1):152-5. PubMed ID: 21543159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant endocrine therapy for breast cancer: how long is long enough?
    Jankowitz RC; Davidson NE
    Oncology (Williston Park); 2013 Dec; 27(12):1210-6, 1224. PubMed ID: 24624537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine therapy for advanced breast cancer.
    Shah PD; Dickler MN
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):214-23. PubMed ID: 25003351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.